{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:39Z","timestamp":1793916039606,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr &amp; Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/objectives<\/jats:title>\n                <jats:p>We aimed to evaluate the relationship between BMI and the risk of renal disease in patients with type 2 diabetes in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects\/methods<\/jats:title>\n                <jats:p>Participants were divided into six baseline BMI categories: &lt;18.5 (underweight, <jats:italic>n<\/jats:italic>\u2009=\u200958); \u226518.5 to &lt;25 (normal, <jats:italic>n<\/jats:italic>\u2009=\u20092894); \u226525 to &lt;30 (overweight, <jats:italic>n<\/jats:italic>\u2009=\u20094340); \u226530 to &lt;35 (obesity grade 1, <jats:italic>n<\/jats:italic>\u2009=\u20092265); \u226535 to &lt;40 (obesity grade 2, <jats:italic>n<\/jats:italic>\u2009=\u2009744); and \u226540\u2009kg\/m<jats:sup>2<\/jats:sup> (obesity grade 3, <jats:italic>n<\/jats:italic>\u2009=\u2009294); those underweight were excluded. The composite outcome \u201cmajor renal event\u201d was defined as development of new macroalbuminuria, doubling of creatinine, end stage renal disease, or renal death. These outcomes and development of new microalbuminuria were considered individually as secondary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During 5-years of follow-up, major renal events occurred in 487 (4.6%) patients. The risk increased with higher BMI. Multivariable-adjusted HRs (95% CIs), compared to normal weight, were: 0.91 (0.72\u20131.15) for overweight; 1.03 (0.77\u20131.37) for obesity grade 1; 1.42 (0.98\u20132.07) for grade 2; and 2.16 (1.34\u20133.48) for grade 3 (<jats:italic>p<\/jats:italic> for trend\u2009=\u20090.006). These findings were similar across subgroups by randomised interventions (intensive versus standard glucose control and perindopril-indapamide versus placebo). Every additional unit of BMI over 25\u2009kg\/m<jats:sup>2<\/jats:sup> increased the risk of major renal events by 4 (1\u20136)%. Comparable results were observed with the risk of secondary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Higher BMI is an independent predictor of major renal events in patients with type 2 diabetes. Our findings encourage weight loss to improve nephroprotection in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41387-017-0012-y","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T11:53:31Z","timestamp":1515671611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Associations between body mass index and the risk of renal events in patients with type 2 diabetes"],"prefix":"10.1038","volume":"8","author":[{"given":"Kamel","family":"Mohammedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"NCD Risk Factor Collaboration.","year":"2016","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513\u20131530 (2016).","journal-title":"Lancet"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","volume":"387","author":"NCD Risk Factor Collaboration.","year":"2016","unstructured":"NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387, 1377\u20131396 (2016).","journal-title":"Lancet"},{"issue":"16","key":"12_CR3","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640\u20131645 (2009).","journal-title":"Circulation"},{"issue":"1 Suppl.","key":"12_CR4","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2013.11.001","volume":"63","author":"AJ Collins","year":"2014","unstructured":"Collins, A. J. et al. US renal data system 2013 annual data report. Am. J. Kidney Dis. 63(1 Suppl.), A7 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1681\/ASN.V1261211","volume":"12","author":"JR Henegar","year":"2001","unstructured":"Henegar, J. R., Bigler, S. A., Henegar, L. K., Tyagi, S. C. & Hall, J. E. Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 12, 1211\u20131217 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.ki.5002586","volume":"73","author":"Y Wang","year":"2008","unstructured":"Wang, Y., Chen, X., Song, Y., Caballero, B. & Cheskin, L. J. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 73, 19\u201333 (2008).","journal-title":"Kidney Int."},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1053\/j.ajkd.2015.10.025","volume":"67","author":"T Melsom","year":"2016","unstructured":"Melsom, T. et al. Prediabetes and risk of glomerular hyperfiltration and albuminuria in the general nondiabetic population: a prospective cohort study. Am. J. Kidney Dis. 67, 841\u2013850 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.291.7.844","volume":"291","author":"CS Fox","year":"2004","unstructured":"Fox, C. S. et al. Predictors of new-onset kidney disease in a community-based population. JAMA 291, 844\u2013850 (2004).","journal-title":"JAMA"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"CY Hsu","year":"2006","unstructured":"Hsu, C. Y., McCulloch, C. E., Iribarren, C., Darbinian, J. & Go, A. S. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 144, 21\u201328 (2006).","journal-title":"Ann. Intern. Med."},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1523-1755.2004.00582.x","volume":"65","author":"K Iseki","year":"2004","unstructured":"Iseki, K. et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 65, 1870\u20131876 (2004).","journal-title":"Kidney Int."},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2213-8587(15)00128-X","volume":"3","author":"JL Lu","year":"2015","unstructured":"Lu, J. L. et al. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 3, 704\u2013714 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/2013.jamainternmed.85","volume":"172","author":"A Vivante","year":"2012","unstructured":"Vivante, A. et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch. Intern. Med. 172, 1644\u20131650 (2012).","journal-title":"Arch. Intern. Med."},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s001250100612","volume":"44","author":"ADVANCE Management Committee.","year":"2001","unstructured":"ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia 44, 1118\u20131120 (2001).","journal-title":"Diabetologia"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560\u20132572 (2008).","journal-title":"N. Engl. J. Med."},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829\u2013840 (2007).","journal-title":"Lancet"},{"key":"12_CR16","unstructured":"World Health Organization. Obesity. http:\/\/www.who.int\/topics\/obesity\/en\/ (2017)."},{"key":"12_CR17","unstructured":"KDIGO Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 3(1 Suppl.), 1\u2013150 (2013).."},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"issue":"7","key":"12_CR19","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/MD.0000000000000041","volume":"93","author":"WH Huang","year":"2014","unstructured":"Huang, W. H. et al. High body mass index reduces glomerular filtration rate decline in type II diabetes mellitus patients with stage 3 or 4 chronic kidney disease. Medicine 93(7), e41 (2014).","journal-title":"Medicine"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.2337\/dc08-0971","volume":"31","author":"AO Luk","year":"2008","unstructured":"Luk, A. O. et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 31, 2357\u20132361 (2008).","journal-title":"Diabetes Care"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diabres.2015.01.028","volume":"108","author":"N Belhatem","year":"2015","unstructured":"Belhatem, N. et al. Impact of morbid obesity on the kidney function of patients with type 2 diabetes. Diabetes Res. Clin. Pract. 108, 143\u2013149 (2015).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"F817","DOI":"10.1152\/ajprenal.2000.278.5.F817","volume":"278","author":"A Chagnac","year":"2000","unstructured":"Chagnac, A. et al. Glomerular hemodynamics in severe obesity. Am. J. Physiol. Ren. Physiol. 278, F817\u2013F822 (2000).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2008.02.303","volume":"52","author":"HM Chen","year":"2008","unstructured":"Chen, H. M. et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am. J. Kidney Dis. 52, 58\u201365 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrneph.2016.75","volume":"12","author":"VD D\u2019Agati","year":"2016","unstructured":"D\u2019Agati, V. D. et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat. Rev. Nephrol. 12, 453\u2013471 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/jcp.21856","volume":"221","author":"B Lewko","year":"2009","unstructured":"Lewko, B. & Stepinski, J. Hyperglycemia and mechanical stress: targeting the renal podocyte. J. Cell. Physiol. 221, 288\u2013295 (2009).","journal-title":"J. Cell. Physiol."},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","volume":"59","author":"N Kambham","year":"2001","unstructured":"Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D\u2019Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498\u20131509 (2001).","journal-title":"Kidney Int."},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2006.07.025","volume":"48","author":"HM Chen","year":"2006","unstructured":"Chen, H. M. et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am. J. Kidney Dis. 48, 772\u2013779 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1093\/ndt\/gfp329","volume":"24","author":"DS Goumenos","year":"2009","unstructured":"Goumenos, D. S. et al. Early histological changes in the kidney of people with morbid obesity. Nephrol. Dial. Transplant. 24, 3732\u20133738 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2337\/dc08-0369","volume":"31","author":"E Nerpin","year":"2008","unstructured":"Nerpin, E. et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 31, 1550\u20131555 (2008).","journal-title":"Diabetes Care"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3810\/pgm.2010.05.2148","volume":"122","author":"AA Mavian","year":"2010","unstructured":"Mavian, A. A., Miller, S. & Henry, R. R. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad. Med. 122, 106\u2013117 (2010).","journal-title":"Postgrad. Med."},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00041433-200306000-00008","volume":"14","author":"JE Schaffer","year":"2003","unstructured":"Schaffer, J. E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol. 14, 281\u2013287 (2003).","journal-title":"Curr. Opin. Lipidol."},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1038\/sj.ijo.0802858","volume":"28","author":"JP Montani","year":"2004","unstructured":"Montani, J. P. et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int. J. Obes. Relat. Metab. Disord. 28, S58\u2013S65 (2004).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/HYPERTENSIONAHA.111.175315","volume":"58","author":"MC Foster","year":"2011","unstructured":"Foster, M. C. et al. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension 58, 784\u2013790 (2011).","journal-title":"Hypertension"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","volume":"2","author":"The Look AHEAD Research Group.","year":"2014","unstructured":"The Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2, 801\u2013809 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323\u2013334 (2016).","journal-title":"N. Engl. J. Med."},{"key":"12_CR36","doi-asserted-by":"crossref","unstructured":"Marso S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834-1844 (2016).","DOI":"10.1056\/NEJMoa1607141"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.kint.2016.02.039","volume":"90","author":"AR Chang","year":"2016","unstructured":"Chang, A. R. et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. 90, 164\u2013171 (2016).","journal-title":"Kidney Int."},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.soard.2012.10.005","volume":"9","author":"CC Hou","year":"2013","unstructured":"Hou, C. C. et al. Improved renal function 12 months after bariatric surgery. Surg. Obes. Relat. Dis. 9, 202\u2013206 (2013).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1681\/ASN.2006080917","volume":"17","author":"M Navarro-Diaz","year":"2006","unstructured":"Navarro-Diaz, M. et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J. Am. Soc. Nephrol. 17, S213\u2013S217 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1373\/clinchem.2005.0525144","volume":"52","author":"GL Myers","year":"2006","unstructured":"Myers, G. L. et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin. Chem. 52, 5\u201318 (2006).","journal-title":"Clin. Chem."},{"key":"12_CR42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5694\/j.1326-5377.2007.tb01357.x","volume":"187","author":"TH Mathew","year":"2007","unstructured":"Mathew, T. H., Johnson, D. W. & Jones, G. R. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Med. J. Aust. 187, 459\u2013463 (2007).","journal-title":"Med. J. Aust."}],"container-title":["Nutrition &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0012-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:15:25Z","timestamp":1671534925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0012-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1038\/s41387-017-0012-y","relation":{},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]},"assertion":[{"value":"6 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kamel Mohammedi reports personal fees from Novo-Nordisk, outside the submitted work; Prof. John Chalmers reports grants and personal fees from Servier, outside the submitted work; Prof. Giuseppe Mancia reports personal fees from Boehringer Ingelheim, personal fees from CVRx, personal fees from Daiichi Sankyo, personal fees from Medtronic, personal fees from Merck & Co., personal fees from Menarini, personal fees from Novartis, personal fees from Servier, outside the submitted work; Prof. Michel Marre reports grants and personal fees from Novo Nordisk, grants and personal fees from Sanofi, grants and personal fees from Eli Lilly, personal fees from Servier, grants and personal fees from Merck Sharp and Dohme, personal fees from Abbott, grants and personal fees from Novartis, personal fees from Astra Zeneca, outside the submitted work; Prof. Neil Poulter reports grants from the George Institute, grants from British Heart Foundation\/Diabetes UK\/The George Institute, during the conduct of the study; grants from The George Institute, grants from BHF\/DUK\/The George Institute, outside the submitted work; Prof. Bryan Williams reports personal fees from servier, outside the submitted work; and Prof. Mark Woodward reports personal fees from Amgen, outside the submitted work. No other potential conflict of interest relevant to this article was reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"7"}}